Literature DB >> 34537933

The protective effects of 17-β estradiol and SIRT1 against cardiac hypertrophy: a review.

Zahra Hajializadeh1, Mohammad Khaksari2.   

Abstract

One of the major causes of morbidity and mortality worldwide is cardiac hypertrophy (CH), which leads to heart failure. Sex differences in CH can be caused by sex hormones or their receptors. The incidence of CH increases in postmenopausal women due to the decrease in female sex hormone 17-β estradiol (E2) during menopause. E2 and its receptors inhibit CH in humans and animal models. Silent information regulator 1 (SIRT1) is a NAD+-dependent HDAC (histone deacetylase) and plays a major role in biological processes, such as inflammation, apoptosis, and oxidative stress responses. Probably SIRT1 because of these effects, is one of the main suppressors of CH and has a cardioprotective effect. On the other hand, estrogen and its agonists are highly efficient in modulating SIRT1 expression. In the present study, we review the protective effects of E2 and SIRT1 against CH.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  17-β estradiol; Cardiac hypertrophy; Estrogen receptors; SIRT1

Mesh:

Substances:

Year:  2021        PMID: 34537933     DOI: 10.1007/s10741-021-10171-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  125 in total

Review 1.  Does load-induced ventricular hypertrophy progress to systolic heart failure?

Authors:  Kambeez Berenji; Mark H Drazner; Beverly A Rothermel; Joseph A Hill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07       Impact factor: 4.733

Review 2.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Circulation       Date:  2015-04-21       Impact factor: 29.690

Review 3.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

Authors:  Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Journal:  Pharmacol Ther       Date:  2010-05-12       Impact factor: 12.310

Review 4.  Gender differences in cardiac hypertrophic remodeling.

Authors:  Mario Patrizio; Giuseppe Marano
Journal:  Ann Ist Super Sanita       Date:  2016 Apr-Jun       Impact factor: 1.663

Review 5.  Mechanotransduction in cardiac hypertrophy and failure.

Authors:  Robert C Lyon; Fabian Zanella; Jeffrey H Omens; Farah Sheikh
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

Review 6.  Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.

Authors:  Julie R McMullen; Garry L Jennings
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-04       Impact factor: 2.557

7.  Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.

Authors:  Cinzia Perrino; Sathyamangla V Naga Prasad; Lan Mao; Takahisa Noma; Zhen Yan; Hyung-Suk Kim; Oliver Smithies; Howard A Rockman
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

Review 8.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 9.  The role of autophagy in angiotensin II-induced pathological cardiac hypertrophy.

Authors:  Lichun Zhou; Baohua Ma; Xiuzhen Han
Journal:  J Mol Endocrinol       Date:  2016-09-12       Impact factor: 5.098

10.  Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program.

Authors:  Derk Frank; Christian Kuhn; Benedikt Brors; Christiane Hanselmann; Mark Lüdde; Hugo A Katus; Norbert Frey
Journal:  Hypertension       Date:  2007-12-24       Impact factor: 10.190

View more
  5 in total

1.  A Systematic Review and Meta-Analysis of Phytoestrogen Protects Against Myocardial Ischemia/Reperfusion Injury: Pre-Clinical Evidence From Small Animal Studies.

Authors:  Yumeng Wang; Xintian Shou; Zongjing Fan; Jie Cui; Donghua Xue; Yang Wu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

2.  Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice.

Authors:  Oluwamolakun Bankole; Ilaria Scambi; Edoardo Parrella; Matilde Muccilli; Roberta Bonafede; Ermanna Turano; Marina Pizzi; Raffaella Mariotti
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

3.  Cold Exposure Induces Intestinal Barrier Damage and Endoplasmic Reticulum Stress in the Colon via the SIRT1/Nrf2 Signaling Pathway.

Authors:  Jingru Guo; Huijie Hu; Zhuo Chen; Jing Xu; Junshu Nie; Jingjing Lu; Li Ma; Hong Ji; Jianbin Yuan; Bin Xu
Journal:  Front Physiol       Date:  2022-04-20       Impact factor: 4.755

4.  Downregulation of amphiregulin improves cardiac hypertrophy via attenuating oxidative stress and apoptosis.

Authors:  Mingyue Ji; Yun Liu; Zhi Zuo; Cheng Xu; Li Lin; Yong Li
Journal:  Biol Direct       Date:  2022-08-22       Impact factor: 7.173

5.  Dipeptide IF and Exercise Training Attenuate Hypertension in SHR Rats by Inhibiting Fibrosis and Hypertrophy and Activating AMPKα1, SIRT1, and PGC1α.

Authors:  Jou-Hsuan Ho; Rathinasamy Baskaran; Ming-Fu Wang; Zuhair M Mohammedsaleh; Hong-Siang Yang; Balamuralikrishnan Balasubramanian; Wan-Teng Lin
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.